Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 35 of 65 · 3115 articles
Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with...
Parents and clinicians may wonder whether stressful events in early life increase a child’s long-term IBD risk. This large prospective study found no evidence that the measured early maternal or family adverse events...
This study describes a novel nanoparticle "nanomachine" approach aimed at fixing gut microbial and barrier dysfunction in IBD models and, by doing so, reducing secondary kidney injury—an intersection (gut–kidney axis)...
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
The study proposes new biomarker candidates (C5AR1, KDM2A, HCAR3) and microbiota-derived metabolites that might interact with those targets. If validated, that could guide future diagnostic tests or microbiome-targeted...
Distinguishing IBD from gastrointestinal tuberculosis is challenging in regions where GITB is common; histologic markers like basal plasmacytosis and eosinophilia on mucosal biopsy could help guide diagnosis when...
Researchers are exploring new small molecules that might modulate T cells in IBD. This study found lab evidence of T‑cell inhibition for several compounds but no therapeutic benefit in a mouse colitis model, so these...
People with IBD may care because this study connects a genetic risk region to a molecular mechanism that restrains inflammation in T cells, offering a potential new biological clue about disease causes and future...
LRMDA may be a previously unrecognized protein important for mucus production and intestinal barrier integrity — processes directly relevant to IBD flares, infection risk, and colorectal cancer development. Understanding...
Improving accuracy of IBD case identification in EMRs can make research and registries more reliable, reduce misclassification, and help ensure studies and quality programs use the right patient groups.
PSC patients commonly experience multiple symptoms that meaningfully affect mental and physical quality of life. Recognizing and measuring total symptom burden could improve research and clinical attention to...
If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease and Research and clinical trials. The original article is from firstwordpharma.com.
This article reports that Amgen is ending a Crohn’s disease target-discovery collaboration with TScan, which could slow or change an industry pathway for immune-targeted therapies discovered through that partnership....
Rising IBD prevalence across Asia means more people will need diagnosis, long-term care, and health-system resources; patterns differ by country and by Crohn's disease versus ulcerative colitis, which affects planning...
Quantitative, rapid stool tests could make it easier to track intestinal inflammation without central lab delays. If translated to clinical use, SERS-enhanced lateral-flow assays might allow more frequent, point-of-care...
The study points to serum protein panels and tissue expression of glypican-6 (GPC6) as potential tools to diagnose or predict intestinal strictures in Crohn disease, which could help detect fibrosis earlier and guide...
A blood test that more reliably distinguishes UC from CD could reduce diagnostic uncertainty and help guide appropriate long‑term management for people with colonic inflammatory bowel disease.
People with IBD and their clinicians may be interested because some studies report higher prostate cancer incidence in IBD populations, and this review explores biological mechanisms that could explain a link while...
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...
The trial could show whether a smart-label app plus clinician alerts improves medication adherence and downstream clinical outcomes for people with Crohn's disease or ulcerative colitis starting oral or subcutaneous...
A new Phase 3 trial is testing duvakitug as a potential induction therapy for moderate-to-severe ulcerative colitis. Trial results could add another treatment option if the drug proves safe and effective.
Researchers are testing whether baseline fecal microbiome profiles can predict who with mild ulcerative colitis will benefit from a specific prebiotic supplement. If validated, this approach could move dietary therapy...
An expanded access program can allow people with Crohn's disease or ulcerative colitis to access upadacitinib before local approval when no other suitable treatments exist.
The paper suggests a new molecular link—low ALIX expression—to inflammatory cell death (pyroptosis) that might help explain mucosal inflammation in ulcerative colitis. If validated, that pathway could point to biomarkers...
The study suggests acetate (sodium acetate) can protect intestinal cells and reshape the gut microbiota in preclinical models of ulcerative colitis, pointing to a potential microbiome-linked therapeutic avenue that might...
This study suggests an environmental fungicide can disrupt gut microbes and reduce beneficial microbial tryptophan metabolites, promoting colitis in mice; dietary tryptophan reversed those effects in the model.
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
Microbiota-targeting treatments are an active area of IBD research, and biomaterials may help overcome delivery challenges that limit current microbiome therapies. Advances here could improve how well these approaches...
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...
A new chemiluminescent probe may help researchers detect and visualize peroxynitrite, a reactive species linked to inflammation in ulcerative colitis, which could aid research into disease mechanisms and early detection...
The studies identify a metabolic reason why the inflamed gut struggles to heal: inflammation reduces an enzyme (QPRT) needed for NAD+ production, starving regenerating intestinal cells of energy. That suggests...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Research and clinical trials.
A dedicated Crohn’s and Colitis Center can coordinate advanced diagnostics, medical and surgical care, nutrition, and mental-health support — all of which can improve symptom management and quality of life. It also...
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...
The study introduces a phylogeny-aware AI method that may improve detection and interpretation of microbiome signatures linked to IBD and colorectal cancer, which could help research into microbial biomarkers relevant to...
The work suggests a new mechanism linking macrophage-driven ECM remodeling to protection of enteric neurons and reduced colitis in preclinical models, which could point to future therapies aimed at preventing neuronal...
Unaffected family members often worry about their own risk and may make dietary changes based on beliefs rather than evidence. Understanding these perceptions can help clinicians give clearer, balanced guidance about...
This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials...
The review outlines new research tools for investigating whether mycobacteria contribute to Crohn’s disease and how the microbiome might influence infection and intestinal inflammation, which could eventually inform...
If validated, blood protein signatures that appear years before symptoms could help identify people at higher risk of Crohn’s disease and point to lifestyle or dietary measures that alter early biology.
The study suggests a specific microbial metabolite, 3‑HPA, can link cold exposure to worse colitis by changing the microbiome and harming epithelial cell mitochondria and barrier function — a possible new mechanistic...
A locally delivered rifamycin formulation reduced macroscopic and microscopic colonic damage in an acute rat model of colitis, suggesting a potential new local therapeutic approach worth further preclinical evaluation.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...
Pouchitis is a common, sometimes chronic complication after IPAA surgery for ulcerative colitis and can substantially affect quality of life. If topical 5-ASA prevents pouchitis, it could offer a simple prophylactic...
This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure...
